Log in or Sign up for Free to view tailored content for your specialty!
Liver Injury/Regeneration News
FDA rejects expanded use of Dynavax’s four-dose hepatitis B vaccine for hemodialysis
The FDA has declined to approve Dynavax’s supplemental biologics license application for the expanded use of its four-dose hepatitis B vaccine regimen in adult patients on hemodialysis, according to a manufacturer’s press release.
Women with concurrent MASLD, alcohol-related liver disease have 83% higher risk for death
Women with concurrent metabolic dysfunction-associated steatotic liver disease and alcohol-related liver disease had an 83% greater risk for all-cause mortality than men and those with ALD alone had 160% greater risk, data showed.
Log in or Sign up for Free to view tailored content for your specialty!
‘Significant differences’ reported by race, ethnicity in transplant rates for MASH-HCC
BOSTON — Hispanic and Asian patients with metabolic dysfunction-associated steatohepatitis and hepatocellular carcinoma were less likely to undergo liver transplantation compared with other races and ethnicities, data showed.
Response to treatment for AKI improved 90-day survival in patients waitlisted for LT
BOSTON — Response to treatment for acute kidney injury correlated with improved 90-day survival and shorter lengths of hospital stay among patients with cirrhosis waitlisted for liver transplant, according to data at The Liver Meeting.
‘Downstream effects’ of alcohol use disorder swell in wake of COVID-19
VANCOUVER, British Columbia — With alcohol-related disease still on the rise after surging during the COVID-19 pandemic, an expert here discussed treatment options, including liver transplantation, for patients with alcoholic hepatitis.
Former Smash Mouth singer’s death underscores need for liver disease awareness
After nearly a decade of health problems, Steve Harwell, former lead singer and frontman for the band Smash Mouth, died Sept. 4 at age 56, which the band’s manager, Robert Hayes, said was caused by acute liver failure.
FDA approves Veklury as first antiviral COVID-19 treatment for all liver disease stages
The FDA expanded its approval of Gilead Sciences’ antiviral, Veklury, for the treatment of COVID-19 in patients with mild, moderate and severe hepatic impairment, without requiring dose adjustments, according to a manufacturer release.
Time-restricted eating may be ‘promising management option’ in patients with NAFLD, NASH
Modifying the timing of daily energy intake may improve metabolic health and restore natural circadian rhythms among patients with nonalcoholic fatty liver disease, according to a review published in Gut.
History of drug allergies poses risk for ‘fatal outcome’ in drug-induced liver injury
In patients with idiosyncratic drug-induced liver injury, previous history of an allergic reaction related to drugs correlated with worse clinical outcomes, including death, according to data presented at the EASL Congress.
Risk for alcohol-related hospitalization fourfold higher in offspring of parents with ALD
Children of parents with alcohol-related liver disease had up to a more than fourfold increased risk for alcohol-related hospitalization, despite a low absolute risk for developing alcohol-related liver disease.
-
Headline News
Q&A: ‘We have to be worried’ about decline in measles vaccination
November 19, 20244 min read -
Headline News
Physicians encouraged to ‘embrace’ technology in practice management
November 19, 20245 min read -
Headline News
Artificial neural network has ‘excellent’ performance in predicting COPD exacerbations
November 20, 20242 min read
-
Headline News
Q&A: ‘We have to be worried’ about decline in measles vaccination
November 19, 20244 min read -
Headline News
Physicians encouraged to ‘embrace’ technology in practice management
November 19, 20245 min read -
Headline News
Artificial neural network has ‘excellent’ performance in predicting COPD exacerbations
November 20, 20242 min read